NASDAQ:DRRX - DURECT Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.51 -0.03 (-1.18 %) (As of 01/17/2020 04:00 PM ET) Add Compare Today's Range$1.90Now: $2.51▼$2.6050-Day Range$1.88MA: $2.49▼$3.8052-Week Range$0.50Now: $2.51▼$3.95Volume5.65 million shsAverage Volume3.25 million shsMarket Capitalization$482.83 millionP/E RatioN/ADividend YieldN/ABeta1.92 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX Previous Symbol CUSIPN/A CIK1082038 Webhttp://www.durect.com/ Phone408-777-1417Debt Debt-to-Equity Ratio1.04 Current Ratio1.81 Quick Ratio1.72Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.56 million Price / Sales26.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.12 per share Price / Book20.92Profitability EPS (Most Recent Fiscal Year)($0.16) Net Income$-25,320,000.00 Net Margins-105.07% Return on Equity-119.34% Return on Assets-37.83%Miscellaneous Employees88 Outstanding Shares192,362,000Market Cap$482.83 million Next Earnings Date3/5/2020 (Estimated) OptionableOptionable Receive DRRX News and Ratings via Email Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:DRRX Rates by TradingView DURECT (NASDAQ:DRRX) Frequently Asked Questions What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) issued its quarterly earnings results on Monday, November, 4th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, missing the Zacks' consensus estimate of $0.02 by $0.03. The specialty pharmaceutical company had revenue of $10.76 million for the quarter, compared to the consensus estimate of $7.78 million. DURECT had a negative return on equity of 119.34% and a negative net margin of 105.07%. View DURECT's Earnings History. When is DURECT's next earnings date? DURECT is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for DURECT. What price target have analysts set for DRRX? 3 Wall Street analysts have issued 12 month target prices for DURECT's stock. Their forecasts range from $2.10 to $5.50. On average, they expect DURECT's share price to reach $4.20 in the next twelve months. This suggests a possible upside of 67.3% from the stock's current price. View Analyst Price Targets for DURECT. What is the consensus analysts' recommendation for DURECT? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DURECT. Has DURECT been receiving favorable news coverage? News headlines about DRRX stock have trended somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. DURECT earned a media sentiment score of -1.2 on InfoTrie's scale. They also assigned media stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for DURECT. Are investors shorting DURECT? DURECT saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 4,120,000 shares, an increase of 30.8% from the December 15th total of 3,150,000 shares. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is presently 3.7 days. Currently, 2.6% of the shares of the company are sold short. View DURECT's Current Options Chain. Who are some of DURECT's key competitors? Some companies that are related to DURECT include Pacira Biosciences (PCRX), Zymeworks (ZYME), Tricida (TCDA), Arvinas (ARVN), Akcea Therapeutics (AKCA), Ligand Pharmaceuticals (LGND), Constellation Pharmaceuticals (CNST), Esperion Therapeutics (ESPR), Alder Biopharmaceuticals (ALDR), Amneal Pharmaceuticals (AMRX), Forty Seven (FTSV), Corcept Therapeutics (CORT), Innoviva (INVA), Intra-Cellular Therapies (ITCI) and Dicerna Pharmaceuticals (DRNA). What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Catalyst Pharmaceuticals (CPRX), Geron (GERN), Immunomedics (IMMU), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Inovio Pharmaceuticals (INO) and PTC Therapeutics (PTCT). Who are DURECT's key executives? DURECT's management team includes the folowing people: Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 62)Mr. Matthew J. Hogan, CFO & Sec. (Age 59)Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 62)Mr. Michael H. Arenberg, Chief Financial Officer (Age 49)Dr. John W. Gibson B.S., M.S., VP of Birmingham Operations & Principal Scientist Who are DURECT's major shareholders? DURECT's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (4.06%), Beirne Wealth Consulting Services LLC (0.86%), Assenagon Asset Management S.A. (0.05%) and Alpine Global Management LLC (0.05%). Company insiders that own DURECT stock include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Institutional Ownership Trends for DURECT. Which institutional investors are selling DURECT stock? DRRX stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Assenagon Asset Management S.A.. View Insider Buying and Selling for DURECT. Which institutional investors are buying DURECT stock? DRRX stock was purchased by a variety of institutional investors in the last quarter, including Beirne Wealth Consulting Services LLC and Alpine Global Management LLC. Company insiders that have bought DURECT stock in the last two years include First Eagle Investment Managem, James E Brown, Jon S Saxe and Michael Arenberg. View Insider Buying and Selling for DURECT. How do I buy shares of DURECT? Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $2.51. How big of a company is DURECT? DURECT has a market capitalization of $482.83 million and generates $18.56 million in revenue each year. The specialty pharmaceutical company earns $-25,320,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. DURECT employs 88 workers across the globe.View Additional Information About DURECT. What is DURECT's official website? The official website for DURECT is http://www.durect.com/. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417. MarketBeat Community Rating for DURECT (NASDAQ DRRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 267 (Vote Outperform)Underperform Votes: 183 (Vote Underperform)Total Votes: 450MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: How is the discount rate different from the Federal Funds rate?
